Market Overview

Global Diagnostic Radiopharmaceuticals & Contrast Media Market Outlook to 2023: High Prevalence of Cancer & Heart Diseases -


The "Global
Diagnostic Radiopharmaceuticals & Contrast Media Market -
Radiopharmaceuticals Segmented by Type of Imaging, Application, Contrast
Media Segmented by Application, Procedure, indication, Geography -
Growth, Trends, and Forecast (2018 - 2023)"
report has been
added to's offering.

The global diagnostic radiopharmaceuticals & contrast media market is
expected to register a CAGR of 9% during the forecast period, 2018 to

The contrast media plays an important role in enhancing the imaging
facilities for better diagnosis. There are many technical innovations in
the market that are expected to contribute to the growth of the market
during the forecast period. There has been an increase in the volume of
the procedures that are being carried out; the CT market by itself is
growing at 6% annually.

Key Highlights

  • High Prevalence of Cancer & Heart Diseases
  • Short Half Life of Radiopharmaceuticals
  • US Lead the Market in North America Region

Notable Developments in the Market

  • Guerbet has acquired the Accurate Medical Therapeutics. The
    acquisition will fuel Guerbet's growth in interventional radiology and
    strengthen its current portfolio
  • GE Healthcare expanded the MRI contrast media product range in Europe
    with macrocyclic agent Clariscan

Key Topics Covered

1. Introduction

2. Research Methodology

3. Executive Summary

4. Key Inferences

5. Market Overview

6. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)

7. Market Segmentation

8. Competitive Landscape

9. Key Players

  • Bayer Healthcare
  • GE Healthcare Guerbet Group
  • Bracco Imaging S.p.A
  • Mallinckrodt PLC
  • Lantheus Holdings Inc.
  • Amag Pharmaceuticals Inc.
  • Medtronic
  • Nordion Inc.

10. Future of the Market

For more information about this report visit

View Comments and Join the Discussion!